Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TETRAPHASE PHARMACEUTICALS INC (TTPH)
|
Add to portfolio |
|
|
|
| Price: |
$2.39
| | Metrics |
| OS: |
7.26
|
M
| |
-215
|
% ROE
|
| Market cap: |
$17.4
|
M
| |
-1390
|
% ROIC
|
|
Net cash:
|
$26.1
|
M
| |
$3.60
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($60.3)
|
M
| |
|
|
|
EBIT
|
($60.8)
|
M
| |
|
|
| EPS |
($11.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Jul-07-13 |
| Revenues | 7.4 | 18.9 | 9.7 | 5.1 | 11.7 | 9.1 | 10.5 | 124.9 |
| Revenue growth | -61.0% | 95.6% | 87.9% | -56.0% | 28.4% | -13.2% | 38.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 131.1 |
| Gross profit | 7.4 | 18.9 | 9.7 | 5.1 | 11.7 | 9.1 | 10.5 | -6.2 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -5.0% |
| Selling, general and administrative | 49.0 | 37.1 | 23.7 | | | | | |
| Research and development | 22.8 | 54.9 | 101.7 | 63.8 | 73.8 | 61.9 | 31.5 | |
| General and administrative | | | | 19.2 | 20.9 | 12.9 | 7.2 | 24.5 |
| EBIT | -67.5 | -73.3 | -115.7 | -77.8 | -83.0 | -65.8 | -28.2 | -112.8 |
| EBIT margin | -915.6% | -387.6% | -1197.1% | -1512.7% | -710.2% | -722.9% | -268.8% | -90.3% |
| Pre-tax income | -70.1 | -72.2 | -114.8 | -77.5 | -83.2 | -66.7 | 0.0 | -119.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 29.6 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -70.1 | -72.2 | -114.8 | -77.5 | -83.2 | -66.7 | -29.6 | -119.7 |
| Net margin | -950.2% | -381.7% | -1187.2% | -1505.9% | -711.9% | -733.6% | -282.6% | -95.9% |
| |
| Diluted EPS | ($22.85) | ($27.48) | ($2.63) | ($2.11) | ($2.36) | ($2.49) | ($1.78) | ($49.36) |
| Shares outstanding (diluted) | 3.1 | 2.6 | 43.6 | 36.7 | 35.3 | 26.8 | 16.7 | 2.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|